Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)

NCT01190267 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

204

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia, Paranoid
Schizophrenia, Disorganized
Schizophrenia, Undifferentiated

Interventions

DRUG: asenapine

Sponsor

Organon and Co